| Bioactivity | ARV-766 is an orally active and potent proteolysis targeting chimera (PROTAC) protein degrader. ARV-766 degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations[1]. |
| Name | ARV-766 |
| CAS | 2750830-09-0 |
| Formula | C45H54FN7O6 |
| Molar Mass | 807.95 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Petrylak D P, et al. A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC)[J]. 2023. |
ARV-766
CAS: 2750830-09-0 F: C45H54FN7O6 W: 807.95
ARV-766 is an orally active and potent proteolysis targeting chimera (PROTAC) protein degrader. ARV-766 degrades wild-ty
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.